Results 11 to 20 of about 1,413,386 (299)
Effects of Chronic Diseases on Quality Adjusted Life Year and Economic Losses of the Elderly [PDF]
Zhongguo quanke yixue, 2022 Background Chronic diseases have become an important public health problem that affects the economic and social development of country and population health. Quantifying the disease and economic burden of the elderly can provide a better understanding of
Xinyue ZHAO, Xiao ZHENG, Yaqing XUE, Weiwei WU, Jiao LU, Chichen ZHANG
doaj +1 more source
Economic burden of the novel coronavirus infection: a systematic review
Фармакоэкономика, 2022 Background. The sudden emergence and rapid spread of the novel coronavirus infection (COVID-19) caused tremendous burden on the health care system including the economic one.
V. M. Timiryanova +3 more
doaj +1 more source
Measuring the Benefits of Healthcare: DALYs and QALYs – Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions [PDF]
International Journal of Health Policy and Management, 2018 Background The measurement of health benefits is a key issue in health economic evaluations. There is very scarce empirical literature exploring the differences of using quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) as ...
Federico Augustovski +8 more
doaj +1 more source
Journal of Rehabilitation Medicine, 2022 Objective: To provide a systematic review of the literature and knowledge base of cost per quality-adjusted life year of physical rehabilitation and care of older persons after hip fracture.
Jonas Ammundsen Ipsen +5 more
doaj +1 more source
Archives of Public Health, 2021 Background One of the most commonly used types of evaluation methods is cost-utility analysis (CUA), using the Quality Adjusted Life Year (QALY) indicator as a preference-based measure for assessing effects of a given programme.
Ewa Kocot +2 more
doaj +1 more source
Liver Cancer, 2020 Introduction: Hepatocellular carcinoma (HCC) is the most common form of liver cancer worldwide and carries a poor prognosis. Historically, sorafenib was the only available systemic treatment for advanced HCC.
Christopher Sherrow +5 more
doaj +1 more source
Levonorgestrel-releasing intrauterine system vs. usual medical treatment for menorrhagia: An economic evaluation alongside a randomised controlled trial [PDF]
, 2014 Objective: To undertake an economic evaluation alongside the largest randomised controlled trial comparing Levonorgestrel-releasing intrauterine device ('LNG-IUS') and usual medical treatment for women with menorrhagia in primary care; and compare the ...
A Stewart +23 more
core +13 more sources
Cost-effectiveness of physical fitness training for stroke survivors [PDF]
, 2018 Background Physical fitness is impaired after stroke, yet fitness training after stroke reduces disability. Several international guidelines recommend that fitness training be incorporated as part of stroke rehabilitation. However, information about cost-
Clifton, E. +3 more
core +3 more sources
Drug Delivery, 2022 Transfersome has been developed to enhance dermal delivery of amniotic mesenchymal stem cell metabolite products (AMSC-MP). AMSC-MP contains many growth factors for managing skin aging, thus improving the quality of an adjusted life year. This study aims
Andang Miatmoko +9 more
doaj +1 more source
Jurnal Manajemen dan Pelayanan Farmasi, 2018 Pharmacoeconomic studies, especially the cost-utility analysis method, require a cost-effectiveness threshold for interpretation of the cost-effectiveness ratios of the study. The cost-effectiveness threshold is determined by each country.
Tri Murti Andayani +3 more
doaj +1 more source